NAMPT阻害剤市場 - パイプライン分析 - 世界の業界分析、規模、シェア、成長、動向、予測（2022年～2031年）

当レポートでは、世界のNAMPT阻害剤市場について調査し、市場の概要とともに、2022年～2031年の予測、相別、用途別、分子タイプ別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 序文

第2章 前提と調査手法

第3章 エグゼクティブサマリー：世界のNAMPT阻害剤市場

第4章 市場概要

• イントロダクション
• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会

第5章 主な洞察

第6章 北米のNAMPT阻害剤市場の分析と予測

• イントロダクション
  • 主な調査結果
• 市場分析、相別、2017年～2031年
  • 第II相
  • 第I/II相
  • 第I相
  • 前臨床
• 市場分析、用途別、2017年～2031年
  • 腫瘍学
  • その他（呼吸器・神経疾患）
• 市場分析、分子タイプ別、2017年～2031年
  • 低分子
  • 生物製剤

第7章 欧州のNAMPT阻害剤市場の分析と予測

第8章 その他の地域のNAMPT阻害剤市場の分析と予測

第9章 競合情勢

• 市場参入企業-競合マトリクス（層および企業規模別）
• 企業プロファイル
  • Onxeo
  • Aqualung Therapeutics
  • Antengene Corporation
  • OncoTartis, Inc.
  • Karyopharm Therapeutics

TMR's report on the global NAMPT inhibitors pipeline analysis market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global NAMPT inhibitors pipeline analysis market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global NAMPT inhibitors pipeline analysis market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the NAMPT inhibitors pipeline analysis market.

The report delves into the competitive landscape of the global NAMPT inhibitors pipeline analysis market. Key players operating in the global NAMPT inhibitors pipeline analysis market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global NAMPT inhibitors pipeline analysis market profiled in this report.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global NAMPT Inhibitors Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Phase Definition
  • 4.1.2. Industry Evolution / Developments
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities

5. Key Insights

• 5.1. Overview on Kay players operating in the market space
• 5.2. Key industry events (mergers, acquisitions, partnerships, etc.)
• 5.3. COVID-19 pandemic impact on industry

6. North America NAMPT Inhibitors Market Analysis and Forecast

• 6.1. Introduction
  • 6.1.1. Key Findings
• 6.2. Market Analysis, by Phase, 2017 - 2031
  • 6.2.1. Phase II
  • 6.2.2. Phase I/II
  • 6.2.3. Phase I
  • 6.2.4. Preclinical
• 6.3. Market Analysis, by Application, 2017 - 2031
  • 6.3.1. Oncology
  • 6.3.2. Others (respiratory and neurology disorders)
• 6.4. Market Analysis, by Type of Molecule, 2017 - 2031
  • 6.4.1. Small Molecules
  • 6.4.2. Biologics

7. Europe NAMPT Inhibitors Market Analysis and Forecast

• 7.1. Introduction
  • 7.1.1. Key Findings
• 7.2. Market Analysis, by Phase, 2017 - 2031
  • 7.2.1. Phase II
  • 7.2.2. Phase I/II
  • 7.2.3. Phase I
  • 7.2.4. Preclinical
• 7.3. Market Analysis, by Application, 2017 - 2031
  • 7.3.1. Oncology
  • 7.3.2. Others (Respiratory and Neurology Disorders)
• 7.4. Market Analysis, by Type of Molecule, 2017 - 2031
  • 7.4.1. Small Molecules
  • 7.4.2. Biologics

8. Rest of the World NAMPT Inhibitors Market Analysis and Forecast

• 8.1. Introduction
  • 8.1.1. Key Findings
• 8.2. Market Analysis, by Phase, 2017 - 2031
  • 8.2.1. Phase II
  • 8.2.2. Phase I/II
  • 8.2.3. Phase I
  • 8.2.4. Preclinical
• 8.3. Market Analysis, by Application, 2017 - 2031
  • 8.3.1. Oncology
  • 8.3.2. Others (Respiratory and Neurology Disorders)
• 8.4. Market Analysis, by Type of Molecule, 2017 - 2031
  • 8.4.1. Small Molecules
  • 8.4.2. Biologics

9. Competition Landscape

• 9.1. Market Player - Competition Matrix (by tier and size of companies)
• 9.2. Company Profiles
  • 9.2.1. Onxeo
    • 9.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 9.2.1.2. Product Portfolio
    • 9.2.1.3. SWOT Analysis
    • 9.2.1.4. Strategic Overview
  • 9.2.2. Aqualung Therapeutics
    • 9.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 9.2.2.2. Product Portfolio
    • 9.2.2.3. SWOT Analysis
    • 9.2.2.4. Strategic Overview
  • 9.2.3. Antengene Corporation
    • 9.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 9.2.3.2. Product Portfolio
    • 9.2.3.3. SWOT Analysis
    • 9.2.3.4. Strategic Overview
  • 9.2.4. OncoTartis, Inc.
    • 9.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 9.2.4.2. Product Portfolio
    • 9.2.4.3. SWOT Analysis
    • 9.2.4.4. Strategic Overview
  • 9.2.5. Karyopharm Therapeutics
    • 9.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 9.2.5.2. Product Portfolio
    • 9.2.5.3. SWOT Analysis
    • 9.2.5.4. Strategic Overview